AU2023435819A1 - Drug combination for treatment of pancreatic cancer - Google Patents
Drug combination for treatment of pancreatic cancerInfo
- Publication number
- AU2023435819A1 AU2023435819A1 AU2023435819A AU2023435819A AU2023435819A1 AU 2023435819 A1 AU2023435819 A1 AU 2023435819A1 AU 2023435819 A AU2023435819 A AU 2023435819A AU 2023435819 A AU2023435819 A AU 2023435819A AU 2023435819 A1 AU2023435819 A1 AU 2023435819A1
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- pancreatic cancer
- drug combination
- drug
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363489221P | 2023-03-09 | 2023-03-09 | |
| US63/489,221 | 2023-03-09 | ||
| PCT/US2023/015813 WO2024186320A1 (en) | 2023-03-09 | 2023-03-21 | Drug combination for treatment of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023435819A1 true AU2023435819A1 (en) | 2025-10-02 |
Family
ID=92675407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023435819A Pending AU2023435819A1 (en) | 2023-03-09 | 2023-03-21 | Drug combination for treatment of pancreatic cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4676463A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2026507878A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250154513A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023435819A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024186320A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596977B (zh) | 2009-05-07 | 2016-06-29 | 明尼苏达大学评议会 | 雷公藤内酯前药 |
| US9150600B2 (en) | 2009-05-07 | 2015-10-06 | Regents Of The University Of Minnesota | Triptolide prodrugs |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| WO2014167581A2 (en) * | 2013-04-01 | 2014-10-16 | Laurus Labs Private Limited | An improved process for the preparation of triptolide prodrugs |
| WO2015127011A1 (en) * | 2014-02-21 | 2015-08-27 | Institute Of Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | C-myc as a biomarker for tumor sensitivity to treatment with rna polymerase ii inhibition |
| US10975146B2 (en) * | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
| US11819498B2 (en) * | 2019-12-30 | 2023-11-21 | Unm Rainforest Innovations | Methods and compositions for treating autophagy related disease states and conditions utilizing AMPK activation |
| WO2021231678A1 (en) * | 2020-05-13 | 2021-11-18 | University Of Massachusetts | Reducing prominin2-mediated resistance to ferroptotic cell death |
-
2023
- 2023-03-21 AU AU2023435819A patent/AU2023435819A1/en active Pending
- 2023-03-21 WO PCT/US2023/015813 patent/WO2024186320A1/en not_active Ceased
- 2023-03-21 EP EP23926583.8A patent/EP4676463A1/en active Pending
- 2023-03-21 JP JP2025551865A patent/JP2026507878A/ja active Pending
- 2023-03-21 KR KR1020257033209A patent/KR20250154513A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026507878A (ja) | 2026-03-06 |
| EP4676463A1 (en) | 2026-01-14 |
| WO2024186320A1 (en) | 2024-09-12 |
| KR20250154513A (ko) | 2025-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3261042A1 (en) | KRAS MACROCYCLIC INHIBITORS FOR CANCER TREATMENT | |
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| EP4119156A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| EP4360649A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| EP4119157A4 (en) | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER | |
| EP3989985A4 (en) | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC CANCER | |
| AU2021372815A9 (en) | Combination treatment of cancer | |
| EP4226945A4 (en) | MEDICATION FOR THE TREATMENT OF CANCER | |
| HK40116983A (en) | Combination therapy for treatment of cancer | |
| HK40120366A (zh) | 癌症的治疗 | |
| HK40128038A (en) | Combination therapies for treatment of cancer | |
| CA3263276A1 (en) | Polytherapy for the treatment of cancer | |
| CA3273958A1 (en) | Methods of treating pancreatic cancer | |
| CA3302582A1 (en) | Molecules for treatment of cancer | |
| EP4363855A4 (en) | DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER | |
| HK40130970A (en) | Combination therapy for the treatment of cancer | |
| CA3271803A1 (en) | Combination therapy for the treatment of cancer | |
| HK40129364A (en) | Combination therapy for the treatment of cancer | |
| HK40114518A (en) | Combination therapy for the treatment of cancer | |
| CA3296090A1 (en) | Psma-targeted radiopharmaceuticals for treatment of cancer | |
| AU2024298849A1 (en) | Psma-targeted radiopharmaceuticals for treatment of cancer | |
| CA3277833A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3264563A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3264839A1 (en) | Medicament for treatment and/or prevention of cancer | |
| CA3265629A1 (en) | Medicament for treatment and/or prevention of cancer |